Guideline change for antiviral therapy reduced the risk of HBV-related HCC development among cirrhotic patients in South Korea

被引：0

作者：

Kim, David ^{[1
]}

Lee, Jae Seung ^{[1
]}

Chun, Ho Soo ^{[1
]}

Lee, Hye Won ^{[1
]}

Kim, Beom Kyung ^{[1
]}

Park, Jun Yong ^{[1
]}

Kim, Do Young ^{[1
]}

Han, Kwang-Hyub ^{[1
]}

Lee, Yu Rim ^{[2
]}

Tak, Won Young ^{[2
]}

Kweon, Young Oh ^{[2
]}

Ahn, Sang Hoon ^{[1
]}

Kim, Seung Up ^{[1
]}

机构：

[1] Yonsei Univ Coll Med, Dept Internal Med, Seoul, South Korea

[2] Kyungpook Natl Univ, Dept Internal Med, Daegu, South Korea

来源：

JOURNAL OF HEPATOLOGY | 2020年 / 73卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

SAT454

引用

页码：S880 / S880

页数：1

共 50 条

[41] Response to: Comment on ''Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis''
Yuan, Peng
Qian, Yeben
Chen, Peng
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 2016
[42] Antiviral therapy inhibited HBV-reactivation and improved long-term outcomes in patients who underwent radiofrequency ablation for HBV-related hepatocellular carcinoma
Liu, Jian
Shen, Hao
Huang, Shengyu
Lin, Jianbo
Yan, Zhenlin
Qian, Guojun
Lu, Zhenghua
Wan, Xuying
Zhang, Fabiao
Wang, Kui
Zhang, Yongjie
Li, Jun
WORLD JOURNAL OF SURGICAL ONCOLOGY, 2023, 21 (01)
[43] Antiviral therapy inhibited HBV-reactivation and improved long-term outcomes in patients who underwent radiofrequency ablation for HBV-related hepatocellular carcinoma
Jian Liu
Hao Shen
Shengyu Huang
Jianbo Lin
Zhenlin Yan
Guojun Qian
Zhenghua Lu
Xuying Wan
Fabiao Zhang
Kui Wang
Yongjie Zhang
Jun Li
World Journal of Surgical Oncology, 21
[44] Change of hepatitis B virus activities with transcatheter arterial chemoembolization therapy in patients with HBV-related hepatocellular carcinoma.
Park, KW
Park, JW
Cho, SH
Park, HS
Lee, WJ
Kim, CM
Lee, DH
HEPATOLOGY, 2004, 40 (04) : 306A - 306A
[45] Meshwork pattern is an important risk factor for development of hepatocellular carcinoma in patients with HBV-related chronic hepatitis and cirrhosis
Habu, D
Nishiguchi, S
Kawamua, E
Lee, C
Enomoto, M
Nakatani, S
Tamori, A
Sakaguchi, H
Takeda, T
Seki, S
Ogami, M
Fukushima, W
Tanaka, T
Asai, H
Shiomi, S
HEPATOLOGY RESEARCH, 2003, 25 (02) : 166 - 173
[46] Risk of HBV reactivation in HCC patients undergoing combination therapy of PD-1 inhibitors and angiogenesis inhibitors in the antiviral era
Wang, Rui
Tan, Guili
Lei, Dingjia
Li, Yadi
Gong, Jiaojiao
Tang, Yao
Pang, Hao
Luo, Huating
Qin, Bo
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (03)
[47] Risk of HBV reactivation in HCC patients undergoing combination therapy of PD-1 inhibitors and angiogenesis inhibitors in the antiviral era
Rui Wang
Guili Tan
Dingjia Lei
Yadi Li
JiaoJiao Gong
Yao Tang
Hao Pang
Huating Luo
Bo Qin
Journal of Cancer Research and Clinical Oncology, 150
[48] First-in-human clinical result of a novel HBV-specific TCR T cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma (HCC)
Wan, Xueshuai
Wu, Wei
Liu, Yunpeng
Du, Shunda
Li, Wei
Quan, Dongmei
Zhang, Ke
Wisskirchen, Karin
Protzer, Ulrike
Zhou, Yuhong
Qu, Xiujuan
JOURNAL OF HEPATOLOGY, 2024, 80 : S99 - S99
[49] Change in health-related quality of life among patients with a reduced ejection fraction initiating guideline-directed medical therapy
Burch, A.
Sears, S. F.
Doring, M.
Gummadi, S.
Robertson, M.
Sanchez, R.
Shroff, G.
Veltmann, C.
EUROPEAN HEART JOURNAL, 2020, 41 : 3431 - 3431
[50] A new model predicts hepatocellular carcinoma in patients with HBV-related decompensated liver cirrhosis and long-term antiviral therapy: a prospective study
Mao, Hao-dan
Zheng, Shu-qin
Yang, Su-hua
Huang, Ze-yu
Xue, Yuan
Zhou, Min
PEERJ, 2023, 11

← 1 2 3 4 5 →